is part of the Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

When will a COVID-19 vaccine be available?

As global communities struggle to manage the impact of the Coronavirus pandemic, all eyes are on the Pharma and Biopharma communities to provide an urgent therapeutic solution

The bad news is, when it comes to vaccine development – there is no such thing as a quick fix. According to the WHO, vaccine development under normal circumstances ‘can take 7-20 years for basic research, clinical testing, regulatory approval, production and distribution’[1].

In recent weeks several Big Pharma players and Biotech’s have announced development plans for vaccines or other therapies for the prevention and treatment of the novel coronavirus, for which no approved vaccine currently exists.

Those working on vaccine development have indicated accelerated timelines for bringing a product to market – on April 14th 2020, two global leaders in vaccine development, GlaxoSmithKline and Sanofi announced they are joining forces to have a vaccine ready within 12-18 months.

In our infographic on COVID-19 vaccine development, we’ve focused on the activities of Moderna Therapeutics, a biotech company headquartered in Cambridge, MA, which has been working on coronavirus vaccines prior to the emergence of the pandemic,using mRNA technology. 

On March 27th, Moderna announced they had begun enrolling Phase 1 trial subjects and on April 16th received an award for up to USD$483 million from US Government agency BARDA for the development of their vaccine candidate.

Based on Moderna's projections, we could see a vaccine come to the market in September 2021.